funds for small biz

SBA launches Virtual Business Recovery Center to assist Texas loan applicants after winter storm

Following Winter Storm Uri, the United States Small Business Association has launched recovery resources for Texas small businesses. Photo via Getty Images

Texas small businesses impacted by Winter Storm Uri are now eligible for up to $2 million in low-interest loans from the U.S. Small Business Administration as a result of President Joe Biden's major disaster declaration last week.

"Getting our businesses and communities up and running after a disaster is our highest priority at SBA," says SBA's acting Administrator Tami Perriello.

According to a release from the SBA, businesses in 77 counties are covered under the declaration for damages incurred during the storm, starting February 11. Loans can be used to repair or replace damaged or destroyed real estate, machinery and equipment, inventory and other business assets. The funds can also be used to make improvements that will protect, prevent, or minimize damage from any future freezes.

Interest rates for businesses start at 3 percent. Loans to private nonprofit organizations will start at 2 percent and homeowners and renters will incur interest at 1.25. All loans are set with 30 years terms.

Loan amounts and terms are determined by the SBA based on each applicant's financial condition.

The SBA will also launch a Virtual Business Recovery Center on February 23 — similar to the Women Business Centers it launched across the country in 2020, but all virtual due to COVID-related health concerns.

Applicants can call or email the virtual center to receive personalized assistance in their online loan applications at 800-659-2955 or FOCWAssistance@sba.gov, from 8 a.m. to 8 p.m.

Assistance will also be provided to help homeowners and renters through a similar Virtual Disaster Loan Outreach Center, which applicants can reach through the same number and email address.

Homeowners are eligible for up to $200,000 to repair or replace damaged or destroyed real estate.Renters and homeowners are also eligible for up to $40,000 for destroyed personal property.

To get started, applicants must contact FEMA at disasterassistance.gov. To download an application visit disasterloanassistance.sba.gov. Individuals who are deaf or hard‑of‑hearing can call 800-877-8339.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News